As part of a pilot campaign, the ACTG AEC Communications Subcommittee is creating a library of ACTG study result slides that will provide insight into the broad range of our work. These short, lay-language slides will be public facing, here on the ACTG public website, and for site use in presentations to various audiences (including Community Advisory Boards). The slide decks below are available for download. We’ll be updating this page with new slide decks, so continue to check back regularly!
A5305: Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEPin MSM, Transgender Women and Cisgender Women
To see study results from A5305 click here.
A5333s: Mechanistic Sub-study of A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
To see results of A5333s click here.
A5336: A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
To see study results from A5336 click here.
A5349: Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis
To see study results from A5349 click here.
A5360 (MINMON): A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to Populations Living with HCV Who Are HCV Treatment Naïve with Evidence of Active HCV Infection
To see study results from A5360 click here.
ACTG REPRIEVE Study Early Stop Announcement
The AIDS Clinical Trials Group (ACTG) is excited to share the news that the REPRIEVE study was stopped early after a daily statin medication was found to reduce the risk of cardiovascular disease among people living with HIV.
REPRIEVE TRIAL Cardiovascular Disease Risk and Prevention in Inflammation: The REPRIEVE Trial in HIV
To see study results from the REPRIEVE trial click here.